Quarterly ResultAug 10, 2026, 04:19 PM
Harrow Q2 Revenue $70.7M, +60% Seq; Reaffirms FY26 Guidance
AI Summary
Harrow, Inc. reported second-quarter 2026 revenue of $70.7 million, a 60% sequential increase and 11% year-over-year growth. Despite a net loss of $17.3 million and negative Adjusted EBITDA, the company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. Key drivers included strong performance from VEVYE, IHEEZO, and TRIESENCE, the launch of BYOOVIZ, and the announced acquisition of TYRVAYA, positioning the company for accelerated growth in the second half of 2026.
Key Highlights
- Q2 2026 revenue reached $70.7 million, up 60% sequentially and 11% year-over-year.
- Reiterated full-year 2026 guidance: revenue $350M-$365M, Adjusted EBITDA $80M-$100M.
- VEVYE revenue was $29.4 million, increasing 40% sequentially and 58% year-over-year.
- IHEEZO revenue was $15.6 million, with unit demand up 44% sequentially and 34% year-over-year.
- Announced acquisition of TYRVAYA, expected to contribute over $30 million in 2027 revenue.
- Net loss for Q2 2026 was $17.3 million, and Adjusted EBITDA was negative $1.2 million.
- Cash and cash equivalents stood at $83.9 million as of June 30, 2026.
- Successfully launched BYOOVIZ in July 2026, entering the U.S. retinal anti-VEGF market.
Price Impact
More from HROW